Laser Treatments for Glaucoma

This trial compares two laser treatments for glaucoma, a condition where increased eye pressure can lead to vision loss. Both treatments aim to lower eye pressure, but Direct Selective Laser Trabeculoplasty (DSLT) is a newer method that might offer more comfort. Participants will be randomly assigned to receive either the new DSLT or the traditional method and will be monitored for a year. This study is suitable for adults with open-angle glaucoma or ocular hypertension who can attend follow-up appointments. As a Phase 4 trial, the treatment is already FDA-approved and proven effective, helping researchers understand how it benefits more patients.

The trial information does not specify if you need to stop your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research shows that both Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT) safely lower eye pressure in people with glaucoma. Although DSLT is a newer method, it is just as safe as SLT. One study found that DSLT effectively reduces eye pressure in people with primary open-angle glaucoma.

Researchers are excited about Direct Selective Laser Trabeculoplasty (SLT) for glaucoma because it offers a more targeted approach compared to traditional treatments. Unlike standard options that rely on broader laser application, Direct SLT precisely targets specific areas of the eye, potentially leading to more efficient fluid drainage and lower eye pressure. This precision could enhance treatment effectiveness while reducing side effects, making it a promising advancement in glaucoma care.

This trial will compare Direct Selective Laser Trabeculoplasty (DSLT) with Traditional Selective Laser Trabeculoplasty (SLT) for treating glaucoma. Research has shown that both DSLT and SLT effectively lower eye pressure, which is crucial for treating glaucoma. One study found that after 12 months, both treatments reduced eye pressure by about 3.2 mm Hg. Early results suggest that DSLT, which participants in one arm of this trial will receive, is not only effective but also safe for patients with primary open-angle glaucoma. Meanwhile, SLT, which participants in another arm will receive, has proven over the years to effectively lower eye pressure and is a standard treatment for glaucoma. DSLT, as a newer method, seems to offer similar benefits and may be more comfortable for patients.²⁴⁶⁷⁸